- Home
- AKA vs SERA Comparison
AKA vs SERA Comparison
Compare AKA & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKA | SERA |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.6M | 130.5M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AKA | SERA |
|---|---|---|
| Price | $11.37 | $3.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $24.33 | N/A |
| AVG Volume (30 Days) | 6.2K | ★ 55.4K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $595,281,000.00 | $95,000.00 |
| Revenue This Year | $5.57 | $25.84 |
| Revenue Next Year | $4.70 | $347.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.44 | 1.06 |
| 52 Week Low | $7.00 | $1.37 |
| 52 Week High | $20.56 | $8.73 |
Technical Indicators
Market Signals| Indicator | AKA | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 57.03 |
| Support Level | $10.25 | $3.38 |
| Resistance Level | $11.58 | $3.66 |
| Average True Range (ATR) | 0.58 | 0.24 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 62.91 | 76.55 |
Price Performance
Historical ComparisonAbout AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.